	US 12,188,018 B2
	Polypeptides useful for gene editing and methods of use
Tyson D. Bowen, Morrisville, NC (US); Alexandra Briner Crawley, Cary, NC (US); Tedd D. Elich, Durham, NC (US); Mark Moore, Durham, NC (US); and Michael Lassner, Portland, OR (US)
Assigned to Life Edit Therapeutics, Inc., Durham, NC (US)
Filed by Life Edit Therapeutics, Inc., Durham, NC (US)
Filed on May 12, 2023, as Appl. No. 18/316,698.
Application 18/316,698 is a continuation of application No. 17/418,498, previously published as PCT/US2019/068079, filed on Dec. 20, 2019.
Claims priority of provisional application 62/932,169, filed on Nov. 7, 2019.
Claims priority of provisional application 62/790,262, filed on Jan. 9, 2019.
Claims priority of provisional application 62/790,261, filed on Jan. 9, 2019.
Claims priority of provisional application 62/790,256, filed on Jan. 9, 2019.
Claims priority of provisional application 62/790,266, filed on Jan. 9, 2019.
Claims priority of provisional application 62/790,258, filed on Jan. 9, 2019.
Claims priority of provisional application 62/785,391, filed on Dec. 27, 2018.
Prior Publication US 2023/0272398 A1, Aug. 31, 2023
Int. Cl. C12N 15/113 (2010.01); C12N 9/22 (2006.01); C12N 9/78 (2006.01)

CPC C12N 15/113 (2013.01) [C12N 9/22 (2013.01); C12N 9/78 (2013.01); C12N 2310/20 (2017.05); C12Y 305/04004 (2013.01)]

28 Claims

1. A fusion protein comprising:

a) a DNA-binding polypeptide that binds to a target polynucleotide; and

b) a deaminase polypeptide, wherein said deaminase polypeptide comprises an amino acid sequence having at least 90% sequence identity to SEQ ID NOs: 399 or 420, and wherein said deaminase polypeptide deaminates at least one nucleotide in said target polynucleotide.